Maternal Mental Health Market (2026 - 2033)

Maternal Mental Health Market Summary

The global maternal mental health market size was valued at USD 7.3 billion in 2025 and is projected to grow from USD 7.9 billion in 2026 to USD 13.1 billion by 2033, growing at a CAGR of 7.5% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 40.0% in 2025. Increased government funding to reduce maternal mortality, an increase in the incidence of post-partum depression, a rise in awareness programs, and efforts to improve practices around maternal mental health.

Maternal mental health is an important issue globally, as it affects not only the well-being of mothers but also the health and development of their children. A recent study by PostpartumDepression.org found that one in seven women will be affected by postpartum depression in 2023. With approximately four million live births annually in the U.S., approximately 600,000 cases of postpartum depression are reported among them.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Maternal mental health is an important issue globally, and efforts are being undertaken to increase the funding related to its research, education, and treatment. The United Chinese Community Enrichment Services Society, also known as S.U.C.C.E.S.S., aims to support postpartum mothers and their families’ mental health in Asian and South Asian immigrant communities. With this funding, S.U.C.C.E.S.S. will be able to improve the referral procedures used by doctors and midwives to connect diverse immigrant communities in the Tri-Cities region of British Columbia with community support, such as mental health services.

Therefore, postpartum women and their families from all over the province will have access to the best medical care that is both trauma-informed and culturally appropriate, as well as support from their service providers. For instance, in September 2025, the Government of Saskatchewan announced new annual funding of CAD 100,000 to the Saskatchewan Perinatal Health Network to develop and deliver a province-wide maternal mental health support program  Moreover, in April 2025, the Black Maternal Health Caucus renewed its efforts to advance maternal health equity by reintroducing the Black Maternal Health Week Resolution and continuing support for the Momnibus legislative package, which has helped secure more than USD 253 million in federal appropriations for maternal health programs since 2023. These investments are aimed at improving maternal health outcomes, expanding access to maternal mental health services, strengthening the perinatal workforce, and reducing racial disparities in maternal care across the United States.

Furthermore, a favorable regulatory and reimbursement environment offers lucrative opportunities during the review period. For instance, Washington, D.C., and 38 states have expanded Medicaid under the Affordable Care Act to provide a continued pathway to postpartum coverage beyond the previously required 60-day period. However, in some of those states and in non-expansion states, women may lose Medicaid coverage postpartum if their incomes exceed 138% of the federal poverty level. Many expansion and non-expansion states have applied for Section 1115 waivers to extend Medicaid beyond 60 days and to higher income levels. For instance, Missouri has an approved 1,115 waivers to offer coverage to a limited population of postpartum individuals with substance use disorders and maternal mental health treatment.

Strong emerging pipelines and the launch of new drugs, such as Zuranolone and Zulresso, are among the primary factors driving the market growth. In September 2025, Biogen Inc. announced that the European Commission approved ZURZUVAE (zuranolone) for the treatment of postpartum depression in adults following childbirth, making it the first and only treatment specifically approved for PPD in the European Union. The approval expanded the commercial footprint of the drug beyond the U.S. market and marked a significant milestone in advancing innovative treatment options for women suffering from postpartum depression.

Market Dynamics

The maternal mental health market is witnessing steady growth, driven by increasing awareness of mental health conditions during pregnancy and the postpartum period, along with growing recognition of their impact on maternal and infant well-being. The rising prevalence of postpartum depression, anxiety disorders, and other perinatal mental health conditions is encouraging greater adoption of screening, counseling, and treatment services. In addition, expanding access to telehealth platforms, increasing government and healthcare initiatives focused on maternal care, and growing investments in women's health services are further supporting market expansion. The integration of mental health support into routine prenatal and postnatal care, coupled with efforts to reduce stigma surrounding maternal mental health, is also contributing to the growing demand for maternal mental health solutions globally.

Analyst Perspective

The maternal mental health market is experiencing steady growth, driven by increasing awareness of perinatal mental health conditions, rising recognition of postpartum depression and anxiety disorders, and growing emphasis on comprehensive maternal care. Healthcare providers are increasingly incorporating mental health screening, counseling, and treatment into prenatal and postnatal care, recognizing their importance in improving outcomes for both mothers and infants. The expanding availability of telehealth services, supportive government initiatives, and growing investments in women's health programs are further supporting market growth. As demand for accessible, personalized, and integrated maternal mental health services continues to rise, companies that focus on innovative therapies, digital health solutions, and expanded access to care will be well positioned to capitalize on long-term growth opportunities.

Disease Indication Insights

Based on disease indication, the pregnancy and postpartum general anxiety segment held a larger share of over 35.0% market in 2025. Generalized Anxiety Disorder (GAD) during the pregnancy and postpartum period is a substantial mental health concern. In recent years, there has been an increased awareness and recognition of perinatal mental health issues, including anxiety disorders, globally. Efforts have been undertaken to improve screening, education, and access to care for pregnant women & new mothers.

Government initiatives will further propel the segment growth over the forecast period. For instance, in 2025, the U.S. Health Resources and Services Administration (HRSA) continued supporting the National Maternal Mental Health Hotline (1-833-TLC-MAMA), which provides 24/7 confidential support in English and Spanish for pregnant and postpartum individuals experiencing mental health challenges.

Since its launch, the hotline has expanded its reach nationwide, improving access to maternal mental health resources and professional support services. Moreover, postpartum depression remains a significant public health concern in the U.S. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 8 women report symptoms of postpartum depression following childbirth.

In addition, the implementation of government regulations will further offer lucrative opportunities during the study period. The Affordable Care Act (ACA) requires insurance plans to cover preventive services, including screening for maternal depression, without cost-sharing. Various organizations and initiatives also aim to raise awareness, provide resources, and support research on PPD & maternal mental health.

The dysthymia segment is expected to witness significant growth during the forecast period owing to the increasing recognition of persistent depressive disorders among women during pregnancy and the postpartum period. Long-lasting depressive symptoms can negatively impact maternal well-being, infant development, and family health, thereby increasing the need for timely diagnosis and treatment. Growing awareness initiatives, improved screening practices, and expanding access to maternal mental health services are supporting segment growth. In addition, healthcare organizations and policymakers are increasingly focusing on improving treatment access for maternal mental health conditions. For instance, in May 2025, the Policy Center for Maternal Mental Health and the George Washington University released the 2025 Maternal Mental Health State Report Cards, highlighting ongoing efforts to improve screening, treatment access, reimbursement, and support programs for maternal mental health conditions across the U.S. Such initiatives are expected to improve diagnosis and treatment rates for depressive disorders, supporting segment growth during the forecast period.

Therapy Insights

The interpersonal psychotherapy (IPT) segment held the largest share of over 20.0% in 2025 and is expected to grow at the fastest CAGR during the forecast period. IPT is a psychotherapy that focuses on improving interpersonal relationships and resolving interpersonal issues. For maternal mental health, IPT can be particularly beneficial as it addresses the specific interpersonal challenges that women may face during the perinatal period.

In addition, IPT is widely accepted as an effective treatment approach for maternal mental health concerns, particularly perinatal mood disorders such as PPD and anxiety, and especially for depressed breastfeeding women. It is recognized and recommended by various professional organizations and guidelines, such as the American Psychiatric Association (APA), the American College of Obstetricians and Gynecologists (ACOG), the National Institute for Health and Care Excellence (NICE), the Canadian Network for Mood and Anxiety Treatments (CANMAT), and Postpartum Support International (PSI)

The antidepressant therapy segment is expected to witness significant growth during the forecast period owing to the increasing prevalence of postpartum depression, anxiety disorders, and other perinatal mental health conditions among women. Antidepressants remain one of the most widely prescribed treatment options for managing moderate to severe maternal mental health disorders due to their proven efficacy in reducing depressive symptoms and improving emotional well-being. Growing awareness regarding maternal mental health, expanding screening programs, and increasing diagnosis rates are contributing to greater treatment adoption. In addition, the availability of newer therapies with improved safety profiles and faster onset of action is supporting segment growth. Healthcare providers are increasingly integrating pharmacological interventions with counseling and behavioral therapies to provide comprehensive care for mothers during pregnancy and the postpartum period. Ongoing research into innovative antidepressant therapies is expected to drive the segment's growth throughout the forecast period.

Regional Insights

North America accounted for the largest revenue share of over 40.0% in 2025 and is expected to grow at the fastest CAGR during the study period. Favorable reimbursement scenarios, rising PPD incidence, expanding awareness programs, and robust healthcare infrastructure are the major factors driving growth in the region. As per the data published by Postpartum Depression, the reported rate of some clinical PPD among new mothers is 10% to 20%. A recent study indicated that one in seven women may develop PPD in the year following childbirth. With over four million live births being reported annually in the U.S., this corresponds to approximately 600,000 PPD diagnoses. In the U.S., approximately 900,000 women who have miscarried or had a stillbirth suffer from PPD annually.

To learn more about this report, Download Free Sample Report

In addition, Texas has expanded postpartum Medicaid coverage to provide eligible mothers with continuous healthcare coverage for up to 12 months following childbirth, significantly improving access to maternal healthcare and mental health services. The extension aims to address postpartum depression, maternal mortality, and other pregnancy-related health challenges by ensuring longer-term access to treatment and support for contraception, providing gender-affirming treatment for trans adolescents, and providing mental health services for youth throughout Texas. Implementation of such legislation will offer lucrative opportunities during the review period.

Asia Pacific Maternal Mental Health Market Trends

The Asia Pacific maternal mental health market is expected to grow significantly over the forecast period, driven by increasing awareness of maternal mental health conditions, improved access to healthcare services, and rising government initiatives focused on women's health and well-being. The growing prevalence of postpartum depression, anxiety disorders, and other perinatal mental health conditions is encouraging healthcare providers to integrate mental health screening and support services into routine maternal care. In addition, expanding telehealth infrastructure, increasing investments in mental healthcare, and growing efforts to reduce stigma around mental health disorders are supporting market growth across the region. For instance, in March 2025, Australia's Center of Perinatal Excellence (COPE) continued expanding the implementation of the National Perinatal Mental Health Guideline and associated screening programs to improve the identification, assessment, and management of mental health conditions during pregnancy and the postpartum period. Furthermore, the presence of large maternal populations and ongoing improvements in healthcare accessibility are expected to create favorable opportunities for market expansion. Such initiatives are expected to support the growth of the maternal mental health market across the Asia Pacific region during the forecast period.

Key Maternal Mental Health Company Insights

Key players in this market are adopting various organic and inorganic strategies, such as partnerships, mergers and acquisitions, geographic expansions, and strategic collaborations, to expand their market presence. Competition among companies is expected to be intense in the global Maternal Mental Health market, driven by the presence of numerous players.

Key Maternal Mental Health Companies

The following key companies have been profiled for this study on the maternal mental health market.

• Therapy Mama

• Canopie

• Pfizer Inc

• Viatris Inc.

• GlaxoSmithKline Inc.

• Alembic Pharmaceuticals Limited

• Mallinckrodt Inc.

• Sage Therapeutics, Inc.

• Bausch Health Companies Inc.

• Magellan Health, Inc.

Recent Developments

• In May 2025, the government of Saskatchewan launched the Wellbeing Course for New and Expecting Parents, a province-wide online therapy program for individuals experiencing perinatal depression, anxiety, and related mental health challenges, supported by CAD 380,000 in provincial funding.

• In February 2026, the Washington State Department of Health announced recipients of its Perinatal Mental Health Access and Capacity Building Grant, providing funding to community organizations to improve access to maternal mental health care, strengthen provider capacity, and support women during and after pregnancy.

Global Maternal Mental Health Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global maternal mental health market report based on disease indication, therapy, and region:

To learn more about this report, Download Free Sample Report

• Disease Indication Outlook (Revenue, USD Million, 2021 - 2033)

  • Postpartum Depression

  • Dysthymia

  • Pregnancy and Postpartum General Anxiety

  • Pregnancy and Postpartum OCD

  • Birth-Related PTSD

  • Others

• Therapy Outlook (Revenue, USD Million, 2021 - 2033)

  • Antidepressants      

    • Selective serotonin reuptake inhibitors (SSRIs)

    • Tricyclic antidepressants (TCAs)

    • Others

  • Interpersonal Psychotherapy (IPT)         

  • Cognitive Behavioral Therapy (CBT)       

  • Others 

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait